Skip to main content

Context Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

CNTX$0.19-6.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Six Months Ended June 30, 2024
Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at January 1, 202415,966,053$15,966$79,909,644$(68,054,590)$11,871,020
Share-based compensation expense——240,007—240,007
Net loss———(3,667,797)(3,667,797)
Balance at March 31, 202415,966,053$15,966$80,149,651$(71,722,387)$8,443,230
Sale of common stock and prefunded warrants, net of offering costs of $5,234,02059,032,25959,03294,699,715—94,758,747
Share-based compensation expense——157,037—157,037
Net loss———(2,254,506)(2,254,506)
Balance at June 30, 202474,998,312$74,998$175,006,403$(73,976,893)$101,104,508
Six Months Ended June 30, 2023
Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at January 1, 202315,966,053$15,966$78,832,779$(44,090,379)$34,758,366
Share-based compensation expense——282,762—282,762
Net loss———(6,308,318)(6,308,318)
Balance at March 31, 202315,966,053$15,966$79,115,541$(50,398,697)$28,732,810
Share-based compensation expense——283,103—283,103
Net loss———(5,011,321)(5,011,321)
Balance at June 30, 202315,966,053$15,966$79,398,644$(55,410,018)$24,004,592
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.